Dopamine D4 receptors potential therapeutic implications in the treatment of schizophrenia

CNS Drugs

Volumn 8, Issue 1, 1997, Pages 1-11

  Shaikh, Sanober ^a   Makoff, Andrew ^a   Collier, David ^a   Kerwin, Robert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUTACLAMOL; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; EMONAPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE; RECEPTOR SUBTYPE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SPIPERONE; SULPIRIDE; ZIPRASIDONE;

ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESISTANCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART; HISTOCHEMISTRY; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; TISSUE DISTRIBUTION;

EID: 0030862561     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708010-00001     Document Type: Article

References (107)

1. Gottesman II. Schizophrenia genesis. New York: WH Freeman, 1991
2. Pickar D. Prospects tor pharmacotherapy of schizophrenia. Lancet 1995; 345: 557-62
3. Kane J, Honigfeld G, Singer J, et al. Clozapine tor the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
4. Carlsson A, Linqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-4
5. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-9
6. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-3
7. Andreasen NC. Brain imaging: applications in psychiatry. Science 1988; 239: 1381-8
8. Zhou QY, Grandy DK, Thambi L, et al. Cloning and expression of human and rat D1 dopamine receptors. Nature 1990; 347: 76-80
9. Dearry A, Gingrich JA, Falardeau P, et al. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 1990; 347: 72-6
10. Sunahara RK, Niznik HB, Weiner DM, et al. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 1990; 347: 80-3
11. Monsma FJJ, Mahan LC, McVittie LD, et al. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci U S A 1990; 87: 6723-7
12. Bunzow JR, Van Tol HH, Grandy DK, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988; 336: 783-7
13. Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146-51
14. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-4
15. Sunahara RK, Guan HC, O'Dowel BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991; 350: 614-9
16. Tiberi M, Jarvie KR, Silvia C, et al. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc Natl Acad Sci U S A 1991; 88: 7491-5
17. Giros B, Sokoloff P, Martres MP, et al. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 1989; 342: 923-6
18. Monsma FJJ, McVittie LD, Gerfen CR, et al. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 1989; 342: 926-9
19. Van Tol HH, Wu CM, Guan HC, et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149-52
20. Wong SK, Parker EM, Ross EM. Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists. J Biol Chem 1990; 265: 6219-24
21. Lichter JB, Barr CL, Kennedy JL, et al. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993; 2: 767-73
22. Matsumoto M, Hidaka K, Tada S, et al. Polymorphic tandem repeats in dopamine D4 receptor are spread over primate species. Biochem Biophys Res Commun 1995; 207: 467-75
23. Livak KJ, Rogers J, Lichter JB. Variability of dopamine D4 receptor (DRD4) gene sequence within and among nonhuman primate species. Proc Natl Acad Sci U S A 1995; 92: 427-31
24. Makoff AJ. Echoes of D4 receptor repeats [letter]. Nature 1992; 360: 424
25. Sokoloff P, Andrieux M, Besancon R, et al. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol 1992; 225: 331-7
26. Sokoloff P, Giros B, Martres MP, et al. Localization and function of the D3 dopamine receptor. Arzneimittel Forschung 1992; 42: 224-30
27. McAllister G, Knowles MR, Patel S, et al. Characterisation of a chimeric hD3/D2 dopamine receptor expressed in CHO cells. FEBS Lett 1993; 324: 81-6
28. Seabrook GR, Patel S, Marwood R, et al. Stable expression of human D3 dopamine receptors in GH4C1 pituitary cells. FEBS Lett 1992; 312: 123-6
29. Freedman SB, Patel S, Marwood R, et al. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther 1994; 268: 417-26
30. Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995; 290: 29-36
31. Lahti RA, Evans DL, Stratman NC, et al. Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 1993; 236: 483-6
32. Asghari V, Schools O, van Kats S, et al. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 1994; 46: 364-73
33. Seeman P, Van Tol HH. Dopamine D4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective. Eur J Pharmacol 1993; 233: 173-4
34. Mills A, Allet B, Bernard A, et al. Expression and characterization of human D4 dopamine receptors in baculovirus-infected insect cells. FEBS Lett 1993; 320: 130-4
35. Chabert C, Cavegn C, Bernard A, et al. Characterization of the functional activity of dopamine ligands at human recombinant dopamine D4 receptors. J Neurochem 1994; 63: 62-5
36. Chio CL, Drong RF, Riley DT, et al. D4 dopamine receptor-mediated signalling events determined in transfected Chinese hamster ovary cells. J Biol Chem 1994; 269: 11813-9
37. MacKenzie RG, Van Leeuwen D, Pugsley TA, et al. Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol 1994; 266: 79-85
38. Tice MA, Hashemi T, Taylor LA, et al. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes. Pharmacol Biochem Behav 1994; 49: 567-71
39. Leysen JE, Gommeren W, Mertens J, et al. Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [1251] 2′-iodospiperone. Psychopharmacology (Berl) 1993; 110: 27-36
40. Weinshank RL, Adham N, Macchi M, et al. Molecular cloning and characterization of a high affinity dopamine receptor (D1 beta) and its pseudogene. J Biol Chem 1991; 266: 22427-35
41. Grandy DK, Zhang YA, Bouvier C, et al. Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. Proc Natl Acad Sci U S A 1991; 88: 9175-9
42. Cox BA, Henningsen RA, Spanoyannis A, et al. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors. J Neurochem 1992; 59: 627-35
43. Stormann TM, Gdula DC, Weiner DM, et al. Molecular cloning and expression of adopamine D2 receptor from human retina. Mol Pharmacol 1990; 37: 1-6
44. Lahti RA, Figur LM, Piercey MF, et al. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol 1992; 42: 432-8
45. Boundy VA, Luedtke RR, Gallitano AL, et al. Expression and characterization of the rat D3 dopamine receptor: pharmacologic properties and development of antibodies. J Pharmacol Exp Ther 1993; 264: 1002-11
46. Grandy DK, Marchionni MA, Makam H, et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 1989; 86: 9762-6
47. Harley EA, Middlemiss DN, Ragan CI. Relationship between inhibition of cyclic AMP production in Chinese hamster ovary cells expressing the rat D2(444) receptor and antagonist/agonist binding ratios. Br J Pharmacol 1995; 115: 1307-13
48. Seeman P, Guan HC, Civelli O, et al. The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. Eur J Pharmacol 1992; 227: 139-46
49. Seeman P, Guan HC, Van Tol HH, et al. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata. Synapse 1993; 14: 247-53
50. Seeman P, Van Tol HH. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 1995; 291: 59-66
51. Kramer M, Zimbroff D, Last B, et al. The effects of a selective D4 antagonist (1-745,870) in acutely psychotic schizophrenic patients. Psychopharmacol Bull 1996; 32: 467
52. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992; 7: 261-84
53. Brucke T, Roth J, Podreka I, et al. Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics [letter]. Lancet 1992; 339: 497
54. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-44
55. Pilowsky LS, Costa DC, Ell PJ, et al. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340: 199-202
56. Pilowsky LS, Costa DC, Ell PJ, et al. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 1231 IBZM SPET (single photon emission tomography) study. Psychol Med 1993; 23: 791-7
57. Baik JH, Picetti R, Saiardi A, et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995; 377: 424-8
58. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55 Suppl. B: 47-52
59. Reynolds GP. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 1992; 13: 116-21
60. Arranz M, Collier D, Sodhi M, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346: 281-2
61. Sodhi MS, Arranz MJ, Curtis D, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7: 169-72
62. O'Malley KL, Harmon S, Tang L, et al. The rat dopamine D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol 1992; 4: 137-46
63. Meador Woodruff JH. Neuroanatomy of dopamine receptor gene expression: potential substrates for neuropsychiatric illness. Clin Neuropharmacol 1995; 18 Suppl. 1: S14-24
64. Matsumoto M, Hidaka K, Tada S, et al. Full-length cDNA cloning and distribution of human dopamine D4 receptor. Brain Res Mol Brain Res 1995; 29: 157-62
65. Meador Woodruff JH, Grandy DK, Van Tol HH, et al. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 1994; 10: 239-48
66. Matsumoto M, Hidaka K, Tada S, et al. Low levels of mRNA for dopamine D4 receptor in human cerebral cortex and striatum. J Neurochem 1996; 66: 915-9
67. Mulcrone J, Kerwin RW. No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics. Neurosci Lett 1996; 219: 163-6
68. Schmajuk NA. Animal models for schizophrenia: the hippocampally lesioned animal. Schizophr Bull 1987; 13: 317-27
69. Murray AM, Hyde TM, Knable MB, et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995; 15: 2186-91
70. Mrzljak L, Bergson C, Pappy M, et al. Localization of dopamine D4 receptors in GABAergic neurons of primate brain. Nature 1996; 381: 245-8
71. Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441-5
72. Buckland PR, O'Donovan MC, McGuffin P. Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology (Berl) 1992; 106: 479-83
73. Reynolds GP, Mason SL. Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem 1994; 63: 1576-7
74. Reynolds GP, Mason SL. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. Eur J Pharmacol 1995; 281: R5-6
75. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744-52
76. Nimgaonkar VL, Wessely S, Tune LE, et al. Response to drugs in schizophrenia: the influence of family history, obstetric complications and ventricular enlargement. Psychol Med 1988; 18: 583-92
77. Lin KM, Poland RE, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989; 146: 1307-11
78. Koreen AR, Lieberman J, Alvir J, et al. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. Arch Gen Psychiatry 1994; 51: 132-8
79. Miller DD, Perry PJ, Cadoret RJ, et al. Effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35: 8-15
80. Pickar D, Owen RRJ, Litman RE, et al. Predictors of clozapine response in schizophrenia. J Clin Psychiatry 1994; 55 Suppl. B: 129-32
81. Catalano M, Nobile M, Novelli E, et al. Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. Biol Psychiatry 1993; 34: 459-64
82. Seeman P, Ulpian C, Chouinard G, et al. Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia. Am J Med Genet 1994; 54: 384-90
83. Nöthen MM, Cichon S, Hemmer S, et al. Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 1994; 3: 2207-12
84. Petronis A, O'Hara K, Barr CL, et al. (G)n-mononucleotide polymorphism in the human D4 dopamine receptor (DRD4) gene. Hum Genet 1994; 93: 719
85. Petronis A, Van Tol HH, Kennedy JL. A Smal PCR-RFLP in the 5′ noncoding region of the human D4 dopamine receptor gene (DRD4). Hum Hered 1994; 44: 58-60
86. Paterson AD, Ying DJ, Schoots O, et al. A novel RFLP at 5′ non-coding region of dopamine D4 receptor gene (DRD4) is not associated with schizophrenia [abstract]. Psychiatr Genet 1995; 5 Suppl. 1: 57
87. Cichon S, Nothen MM, Catalano M, et al. Identification of two novel polymorphisms and a rare deletion variant in human dopamine D4 receptor gene. Psychiatr Genet 1995; 5 (3): 97-103
88. Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine [letter]. Lancet 1993; 341: 116
89. Kennedy JL, Petronis A, Gao J, et al. Genetic studies of DRD4 and clinical response to neuroleptic medications [abstract]. Am J Hum Genet 1994; 55: 3
90. Rietschel M, Naher D, Oberlander H, et al. Testing the hypothesis of an association between clozapine response and allelic association in the dopamine D4 and the serotonin 2A receptor gene [abstract]. Psychiatr Genet 1995; 5 Suppl. 1: 101
91. Shaikh S, Collier DA, Sham P, et al. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet 1995; 60: 541-5
92. Shaikh S, Kerwin R, Sham P, et al. D4 polymorphisms in schizophrenic patients treated with clozapine. Schizophr Res 1995; 15: 165-6
93. McGuffin P, Asherson P, Owen M, et al. The strength of the genetic effect: is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatry 1994; 164: 593-9
94. Kerwin R, Collier DA. The dopamine D4 receptor and schizophrenia: an update. Psychol Med 1996; 26: 221-7
95. Williams J, Spurlock G, McGuffin P, et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a receptor gene. Lancet 1996; 347: 1294-6
96. Benjamin J, Li L, Patterson C, et al. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nat Genet 1996; 12: 81-4
97. Ebstein RP, Novick O, Umansky R, et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet 1996; 12: 78-80
98. La Hoste GJ, Swanson JM, Wigal SB, et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996; 1: 121-4
99. Shaikh S, Gill M, Owen M, et al. Failure to find linkage between a functional polymorphism in the dopamine D4 receptor gene and schizophrenia. Am J Med Genet 1994; 54: 8-11
100. Lim LC, Nothen MM, Korner J, et al. No evidence of association between dopamine D4 receptor variants and bipolar affective disorder. Am J Med Genet 1994; 54: 259-63
101. Adamson MD, Kennedy J, Petronis A, et al. DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls. Am J Med Genet 1995; 60: 199-205
102. Brett PM, Curtis D, Robertson MM, et al. The genetic susceptibility to Gilles de la Tourette syndrome in a large multiple affected British kindred: linkage analysis excludes a role for the genes coding for dopamine D1, D2, D3, D4, D5 receptors, dopamine beta hydroxylase, tyrosinase, and tyrosine hydroxylase. Biol Psychiatry 1995; 37: 533-40
103. Grice DE, Leckman JF, Pauls DL, et al. Linkage disequilibrium between an allele at the dopamine D4 receptor locus and Tourette syndrome, by the transmission-disequilibrium test. Am J Hum Genet 1996; 59: 644-52
104. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995; 15 (1 Suppl. 1): 2-3S
105. Boyfield I, Brown TH, Coldwell MC, et al. Design and synthesis of 2-naphthoate esters as selective dopamine D4 antagonists. J Med Chem 1996; 39: 1946-8
106. Dean B, Hayes W. Decreased cortical serotonin 2A receptors in schizophrenia. Schizophrenia Res 1996; 21: 133-9
107. Sodhi MS, Murray RM. Future therapies for schizophrenia. Exp Opin Ther Patents 1997; 7 (2): 151-65